Terns Pharmaceuticals to host investor webinar on TERN-701 for CML

FOSTER CITY, Calif. - Terns Pharmaceuticals, Inc. (NASDAQ:TERN), a $599 million market cap biotech company, will host an investor educational webinar on September 3, 2025, to discuss its investigational chronic myeloid leukemia (CML) treatment TERN-701 ahead of anticipated data release in the fourth quarter of 2025. According to InvestingPro data, analysts maintain a strong buy consensus on the stock, with price targets ranging from $14 to $34.

The webinar will review the drug candidate’s profile, benchmarks for upcoming Phase 1 data, and its positioning in the CML treatment landscape. TERN-701 is an oral, allosteric BCR-ABL inhibitor targeting the ABL myristoyl pocket.

The company’s leadership team, including CEO Amy Burroughs, Chief Medical Officer Emil Kuriakose, and Chief Development Officer Scott Harris, will lead the presentation.

TERN-701 is currently being evaluated in the CARDINAL trial, a global Phase 1 study assessing safety, tolerability, and efficacy in previously treated chronic phase CML patients. The dose escalation portion completed in January 2025 with no dose limiting toxicities observed up to the maximum dose of 500 mg daily.

The company initiated the dose expansion portion in April 2025, with patients randomized to receive either 320 mg or 500 mg daily, with up to 40 patients per arm. Terns plans to report efficacy and safety data, including six-month major molecular response achievement rate, in the fourth quarter of 2025.

Previously announced interim data from the dose escalation portion showed molecular responses starting at the lowest dose in heavily pre-treated patients with high baseline BCR-ABL transcript levels, according to the press release. No dose limiting toxicities, adverse event-related treatment discontinuations, or dose reductions were reported across all dose escalation cohorts.

Terns Pharmaceuticals is developing a portfolio of small-molecule product candidates for oncology, obesity, and other serious diseases. The stock has shown strong momentum with a 57% gain over the past six months, though InvestingPro analysis indicates the stock is currently trading near its Fair Value. Subscribers can access 8 additional ProTips and a comprehensive Pro Research Report covering what really matters about this emerging biotech company.

In other recent news, Terns Pharmaceuticals has completed enrollment for its Phase 2 FALCON clinical trial of TERN-601, an oral GLP-1 receptor agonist being developed for obesity. The company plans to release topline data from this trial in the fourth quarter of 2025. Additionally, Terns Pharmaceuticals will present further data from its completed Phase 1 study of TERN-601 at the American Diabetes Association’s 85th Scientific Sessions. The Phase 1 results previously indicated statistically significant and dose-dependent weight loss of up to 5.5% over 28 days with once-daily dosing.

In another development, Citizens JMP analyst Silvan Tuerkcan has reiterated a Market Outperform rating for Terns Pharmaceuticals, maintaining a price target of $20.00. This decision is based on encouraging efficacy data for the company’s TERN-701 treatment. Previously, TERN-701 showed positive efficacy trends for refractory patients and those who did not tolerate their TKI treatment, achieving a cumulative MMR rate of 50% at 12 weeks in non-T315I patients. The treatment also reduced BCR::ABL1 transcripts in 88% of MR1+ patients.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.